Abstract:Aim: Recent progress in cancer immunotherapy has shown its promise and prompted researchers to develop novel therapeutic strategies. Dendritic cells (DCs) are professional antigen-presenting cells crucial for initiating adaptive anti-tumor immunity, therefore a promising target for cancer treatment. Here, anti-tumor activities of DC-targeting chemokines were explored in murine colorectal tumor models. Methods: The correlation of chemokine messenger RNA (mRNA) expression with DC markers was analyzed using The Cancer Genome Atlas (TCGA) dataset. Murine colorectal tumor cell lines (CT26 and MC38) stably overexpressing mouse C-C motif chemokine ligand 3 (CCL3), CCL19, CCL21, and X-C motif chemokine ligand 1 (XCL1) were established by lentiviral transduction. The effect of chemokines on tumor cell proliferation/survival was evaluated in vitro by cell counting kit-8 (CCK-8) assay and colony formation assay. Syngeneic subcutaneous tumor models were used to study the effects of these chemokines on tumor growth. Ki-67 expression in tumors was examined by immunohistochemistry. Immune cells in the tumor microenvironment (TME) and lymph nodes were analyzed by flow cytometry. Results: Expression of the four chemokines was positively correlated with the two DC markers [integrin alpha X (ITGAX) and CLEC9A] in human colorectal tumor samples. Tumoral overexpression of DC-targeting chemokines had little or no effect on tumor cell proliferation/survival in vitro while significantly suppressing tumor growth in vivo. Fluorescence-activated cell sorting (FACS) analysis showed that CCL19, CCL21, and XCL1 boosted the ratios of DCs and T cells in CD45+ leukocytes while CCL3 increased the percentage of CD45+ leukocytes in total cells in MC38 tumor. XCL1 had an additional positive effect on antigen uptake by DCs in the TME and antigen transfer to tumor-draining lymph nodes. Conclusions: CCL3, CCL19, CCL21, and XCL1 exhibited potent anti-tumor activities in vivo, although they might differentially regulate immune cells in the TME and antigen transfer to lymph nodes.

Dendritic cell-based immunotherapies and their potential use in colorectal cancer immunotherapy

Progress on Dendritic Cell Vaccines in Tumor Immunotherapy

Current state of knowledge and challenges for harnessing the power of dendritic cells in cancer immunotherapy

The role of dendritic cells in cancer immunity and therapeutic strategies

Dendritic Cell Vaccines for Cancer Immunotherapy: The Role of Human Conventional Type 1 Dendritic Cells

Dendritic Cell-Based Vaccines Against Cancer: Challenges, Advances and Future Opportunities

The current role of dendritic cells in the progression and treatment of colorectal cancer

The Therapeutic Potential of Tackling Tumor-Induced Dendritic Cell Dysfunction in Colorectal Cancer

Dendritic cell-derived exosome (DEX) therapy for digestive system cancers: Recent advances and future prospect

Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications

Dendritic cell biology and its role in tumor immunotherapy

Dendritic Cells in Cancer Immunology and Immunotherapy

Dendritic Cells Based Immunotherapy

Dendritic Cell-Targeting Chemokines Inhibit Colorectal Cancer Progression

Biomaterial-based platforms for in situ dendritic cell programming and their use in antitumor immunotherapy

Dendritic cells as orchestrators of anticancer immunity and immunotherapy

Dendritic cell subsets and implications for cancer immunotherapy

Dendritic cell-based immunotherapy in non-small cell lung cancer: a comprehensive critical review

Biomaterials Facilitating Dendritic Cell‐Mediated Cancer Immunotherapy

Trial watch: dendritic cell vaccination for cancer immunotherapy

Current State of Dendritic Cell-Based Immunotherapy: Opportunities for in vitro Antigen Loading of Different DC Subsets?